We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Rapid development of atypical fibroxanthoma during vismodegib treatment.
- Authors
Giorgini, C.; Barbaccia, V.; Croci, G. A.; Imarisio, I.; Vassallo, C.
- Abstract
The article presents case study of a 83-year-old man who was diagnosed with rapid development of atypical fibroxanthoma during vismodegib treatment. It mentions that vismodegib is a systemic drug for the treatment of advanced, inoperable or metastatic basal cell carcinoma, acting by downregulating the Sonic Hedgehog (SHH) pathway, which is responsible for basal cell carcinoma (BCC) proliferation. It states that the patient had hypertension and Type 2 diabetes mellitus.
- Subjects
XANTHOMA; BASAL cell carcinoma; DOWNREGULATION; TYPE 2 diabetes; HYPERTENSION
- Publication
Clinical & Experimental Dermatology, 2019, Vol 44, Issue 1, p86
- ISSN
0307-6938
- Publication type
Case Study
- DOI
10.1111/ced.13736